Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in localized BRCA-mutant breast cancer
NCT03329937Phase 1Completed
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of niraparib in breast cancer. Primary endpoint: Percentage of Participants With Tumor Response Measured by Breast MRI at 2 months. Started Apr 2018; status: completed.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03329937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329937.